Bausch + Lomb Acquires Elios Vision, Significantly Enhances Glaucoma Treatment Capabilities
Bausch + Lomb Corporation (BLCO)
Company Research
Source: Business Wire
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that an affiliate has acquired Elios Vision, Inc., developer of the ELIOS™ procedure, the first clinically validated, minimally invasive glaucoma surgery (MIGS) procedure using an excimer laser. The acquisition unlocks new opportunities to treat glaucoma effectively in conjunction with cataract surgery without implants and bolsters Bausch + Lomb’s glaucoma portfolio, which features pharmaceutical and surgical approaches.“Today’s announcement further demonstrates our commitment to investing in smart, innovative technologies that enable eye care professionals to better address the evolving needs of their patients,” said Luc Bonnefoy, president, Surgical, Bausch + Lomb. “The ELIOS system offers a differentiated approach for the treatment of glaucoma, a condition expected to increase in prevalence by 4
Show less
Read more
Impact Snapshot
Event Time:
BLCO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLCO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLCO alerts
High impacting Bausch + Lomb Corporation news events
Weekly update
A roundup of the hottest topics
BLCO
News
- Bausch + Lomb Confirms It Is Exploring a Potential Sale [BNN Bloomberg (Canada)]BNN Bloomberg
- Bausch + Lomb Co. (NYSE: BLCO) had its "underperform" rating re-affirmed by analysts at Bank of America Co.. They now have a $18.00 price target on the stock.MarketBeat
- Bausch + Lomb Co. (NYSE: BLCO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $23.00 price target on the stock.MarketBeat
- Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb [Yahoo! Finance]Yahoo! Finance
- Bausch + Lomb Responds to Rumors of a Potential SaleBusiness Wire
BLCO
Earnings
- 10/30/24 - Beat
BLCO
Sec Filings
- 11/1/24 - Form 8-K
- 10/30/24 - Form 10-Q
- 10/30/24 - Form 8-K
- BLCO's page on the SEC website